跳至主要内容
临床试验/NCT03797885
NCT03797885已完成不适用

An Observational Cross-sectional Study to Estimate the Prevalence of Cardiovascular Disease and CV Risk Factors in T2DM Patients Including a Retrospective Phase to Evaluate the Clinical Management of a Subgroup of Patients in the Hospital Setting in Portugal

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 730 人开始时间: 2019年1月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
730
试验地点
1
主要终点
Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis

研究概览

简要总结

This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus. Simultaneously, this study also intends to obtain more information about the management of type 2 diabetes mellitus patients with established cardiovascular disease. This study is non-interventional, which means that will not require participant's further related visits or procedures. The study will collect the participant's clinical data from the current visit and, when applicable, within the last 3 years.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Main study population (Data collection - Prevalence):
  • Signed Informed Consent Form (ICF) obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
  • Male or female patient, age greater or equal to 18 years at the time of signing ICF
  • Patients diagnosed with type 2 diabetes
  • Subgroup (Data collection - Patient management):
  • Patients followed at the hospital setting by the endocrinologist or internal medicine specialist (ambulatory diabetes management) and with available medical records, retrospectively within the last three years
  • Patients with type 2 diabetes mellitus and established cardiovascular disease diagnosed at least three years ago

排除标准

  • Previous participation in this study. Participation is defined as signed ICF
  • Female patient who is pregnant or breast-feeding
  • Patients with type 1 diabetes
  • Participation in a clinical trial within the last 3 years

结局指标

主要结局

Proportion of type 2 diabetes mellitus (T2DM) patients with cardiovascular risk factors (CVRFs) and/or established cardiovascular disease (CVD), regardless the date of diagnosis

时间窗: Baseline (month 0)

Proportion of subjects. CVRFs are defined as a history of one or more of the following criteria: * Overweight or obese * Family history of CVD (1st degree) * Hypertension * Hypercholesterolemia * Low high-density lipoproteins * Hypertriglyceridemia * Smoking habits * Sedentary lifestyle -as per Investigator discretion according to his/her normal practice. CVD is defined as a history of one or more of the following events: * Stroke * Transient ischaemic attack * Ischaemic heart disease including myocardial infarction * Congestive heart failure * Atrial fibrillation * Aortic aneurism * Peripheral or carotid artery disease

次要结局

  • Change in body mass index(During 3 years before baseline (0 to -36 months))
  • Hospital appointments(During 3 years before baseline (0 to -36 months))
  • Change in total cholesterol(During 3 years before baseline (0 to -36 months))
  • Hyperglycaemic episodes(During 3 years before baseline (0 to -36 months))
  • Change in urine albumin(During 3 years before baseline (0 to -36 months))
  • Change in Estimated Glomerular Filtration Rate (eGFR)(During 3 years before baseline (0 to -36 months))
  • Change in high-density lipoprotein cholesterol(During 3 years before baseline (0 to -36 months))
  • Type of pharmacological treatment(During 3 years before baseline (0 to -36 months))
  • Hypoglycaemic episodes(During 3 years before baseline (0 to -36 months))
  • Change in blood pressure(During 3 years before baseline (0 to -36 months))
  • Change in glycosylated hemoglobin (HbA1c)(During 3 years before baseline (0 to -36 months))
  • Change in low-density lipoprotein cholesterol(During 3 years before baseline (0 to -36 months))
  • Presence of T2DM complications (yes/no)(During 3 years before baseline (0 to -36 months))
  • Types of T2DM complications(During 3 years before baseline (0 to -36 months))
  • Hospitalisation episodes(During 3 years before baseline (0 to -36 months))
  • Emergency visits(During 3 years before baseline (0 to -36 months))
  • Change in waist circumference(During 3 years before baseline (0 to -36 months))
  • Change in HbA1c(During 3 years before baseline (0 to -36 months))
  • Change in triglyceride(During 3 years before baseline (0 to -36 months))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验